New York Times' digital subscribers hit 9.91 million, growing by 210K in Q1. Sales reached $594M, up 5.9% Y/Y. Digital ARPU rose to $9.21. CEO Meredith Kopit Levien emphasizes a strong start in 2024. Guidance predicts subscription revenues up by 6%-8% in Q2.
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed across dosing groups.
A young patient passed away from cardiac arrest after receiving Pfizer's experimental gene therapy for Duchenne muscular dystrophy. Pfizer investigates while trials continue, including Phase 3 study. Second death associated with the therapy.
BHP's subsidiary signed Exploration Alliance Agreement with Ivanhoe Electric to explore for copper and other minerals in the US, with a mutual goal of finding new sources for the growing demand. BHP will provide $15M initial funding, with potential for more on a 50/50 basis.